Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -5.58% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -198%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $179.0M 100.0% | $227.0M 100.0% | $274.1M 100.0% | $247.6M 100.0% | $272.3M 100.0% | $303.6M 100.0% | $284.1M 100.0% | $283.4M 100.0% | $273.8M 100.0% | $249.2M 100.0% |
| Cost of Revenue | — | $157.8M 69.5% | $189.3M 69.1% | $171.1M 69.1% | $195.3M 71.7% | $219.3M 72.2% | $202.9M 71.4% | $188.1M 66.4% | $176.0M 64.3% | $169.9M 68.2% |
| Cost of Products | — | — | — | — | — | — | — | — | — | $169.9M 68.2% |
| Gross Profit | $50.2M 28.1% | $69.1M 30.5% | $84.8M 30.9% | $76.5M 30.9% | $76.9M 28.3% | $84.3M 27.8% | $81.2M 28.6% | $95.3M 33.6% | $97.8M 35.7% | $79.3M 31.8% |
| Selling, General & Admin | $50.7M 28.3% | $38.6M 17.0% | $55.2M 20.2% | $41.7M 16.8% | $31.1M 11.4% | $29.7M 9.8% | $25.3M 8.9% | $24.8M 8.7% | $24.3M 8.9% | $22.8M 9.1% |
| Total Operating Expenses | $108.9M 60.8% | $70.7M 31.1% | $92.9M 33.9% | $70.5M 28.5% | $52.7M 19.3% | $53.8M 17.7% | $50.3M 17.7% | $49.1M 17.3% | $45.7M 16.7% | $41.8M 16.8% |
| Operating Income | -$58.7M -32.8% | -$1.5M -0.7% | -$8.2M -3.0% | $6.1M 2.4% | $24.3M 8.9% | $30.5M 10.1% | $31.0M 10.9% | $46.2M 16.3% | $52.1M 19.0% | $37.5M 15.0% |
| Interest & Investment Income | — | — | — | $2.1M 0.8% | $335K 0.1% | $314K 0.1% | $1.7M 0.6% | $1.9M 0.7% | $658K 0.2% | $141K 0.1% |
| Other Income (Expense), net | $1.3M 0.7% | $943K 0.4% | $1.9M 0.7% | $1.4M 0.6% | -$105K -0.0% | $419K 0.1% | $2.9M 1.0% | $2.9M 1.0% | $1.7M 0.6% | $441K 0.2% |
| Pretax Income | -$57.4M -32.0% | -$587K -0.3% | -$6.3M -2.3% | $7.4M 3.0% | $24.2M 8.9% | $30.9M 10.2% | $33.9M 11.9% | $49.1M 17.3% | $53.8M 19.6% | $37.9M 15.2% |
| Income Tax Expense | -$73K -0.0% | $5.7M 2.5% | $1.2M 0.4% | $2.3M 0.9% | $5.5M 2.0% | $7.0M 2.3% | $8.0M 2.8% | $11.4M 4.0% | $16.5M 6.0% | $14.1M 5.7% |
| Net Income | -$57.3M -32.0% | -$6.3M -2.8% | -$7.5M -2.7% | $5.1M 2.1% | $18.7M 6.9% | $23.9M 7.9% | $25.9M 9.1% | $37.7M 13.3% | $37.3M 13.6% | $23.8M 9.6% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.74 | $-0.30 | $-0.37 | $0.25 | $0.93 | $1.19 | $1.29 | $1.84 | $1.83 | $1.18 |
| EPS (Diluted) | $-2.74 | $-0.30 | $-0.37 | $0.25 | $0.92 | $1.19 | $1.29 | $1.84 | $1.82 | $1.17 |
| Weighted Avg Shares (Basic) | 20.9M | 20.6M | 20.4M | 20.3M | 20.2M | 20.1M | 20.0M | 20.5M | 20.3M | 20.2M |
| Weighted Avg Shares (Diluted) | 20.9M | 20.6M | 20.4M | 20.3M | 20.4M | 20.1M | 20.1M | 20.5M | 20.4M | 20.4M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $21000 dividends + $0 buybacks = $21000 returned on -$33M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| PETS | $34M | — | — | 0.2× | -21.1% | 28.1% | -32.0% | -198% | -198% | — | 48 |
Peers = companies sharing PETS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 15-yr range · 6th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 15-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 66.4 | 71.4 | 72.2 | 71.7 | 69.1 | 69.1 | 69.5 | — |
| Gross Profit | 33.6 | 28.6 | 27.8 | 28.3 | 30.9 | 30.9 | 30.5 | 28.1 |
| SG&A | 8.7 | 8.9 | 9.8 | 11.4 | 16.8 | 20.2 | 17.0 | 28.3 |
| Operating Income | 16.3 | 10.9 | 10.1 | 8.9 | 2.4 | -3.0 | -0.7 | -32.8 |
| Income Tax | 4.0 | 2.8 | 2.3 | 2.0 | 0.9 | 0.4 | 2.5 | -0.0 |
| Net Income | 13.3 | 9.1 | 7.9 | 6.9 | 2.1 | -2.7 | -2.8 | -32.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PETS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.